



## Overview

Corbus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat life threatening ("orphan") inflammatory-fibrotic diseases with clear unmet needs. Our lead product Resunab™ is a first-in-class oral anti-inflammatory expected to commence Phase-2a clinical trials for the treatment of cystic fibrosis and scleroderma pending FDA approval of IND.

## Management Team

### Yuval Cohen, PhD

Chief Executive Officer, Director

### Mark A. Tepper, PhD

President & Chief Scientific Officer

### Barbara White, MD

Chief Medical Officer

### Sean Moran, CPA, MBA

Chief Financial Officer

## Recent News

Thursday, November 08, 2018 - 07:00 AM

[Corbus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update](#)

Tuesday, November 06, 2018 - 08:00 AM

[Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in November](#)

Monday, November 05, 2018 - 08:00 AM

[Corbus Pharmaceuticals to Announce Third Quarter 2018 Operational and Financial Results on November 8, 2018](#)

Monday, October 22, 2018 - 08:00 AM

[Corbus Pharmaceuticals Presents Lenabasum Long-Term Open-Label Clinical Data Showing Maintenance of Favorable Safety Profile and Further Improvement in Multiple Efficacy Endpoints in Systemic Sclerosis and Dermatomyositis Phase 2 Studies](#)

Thursday, October 18, 2018 - 04:05 PM

[Corbus Pharmaceuticals Presents Data on Impact of Lenabasum on Inflammation of Airway Macrophages from Cystic Fibrosis Lungs at the 2018 North American Cystic Fibrosis Conference](#)

## DISCLAIMER

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.

## Contact Information

### Corbus Pharmaceuticals Holdings, Inc.

500 River Ridge Drive  
Second Floor  
Norwood, MA 02062

## Nasdaq: CRBP



Share Price	\$6.61
Volume	942.54k
Shares Outstanding	57,206,090
Market Cap	\$378.13m
52 Week High	\$9.96
52 Week Low	\$4.50

as of 11/09/2018